Table 2.

Clinical and Histopathologic Characteristics of the Patients in the Second Prostate Tissue Microarray.

Effect	Level	Number of Patients	Cancer-Specific Survival			Time to Local Recurrence			Time to Metastasis Formation
			Global P	Events	HR with 95% CI	Global P	Events	HR with 95% CI	Global P	Events	HR with 95% CI
PSA (ng/ml)	≤4	18	.168	0	(Ref.)	.196	3	(Ref.)	.335	1	(Ref.)
	4–10	33		2	2 x 105 (0 to >1010)		11	2.70 (0.75–9.75		4	2.74 (0.30–24.73)
	>10	38		4	664 (0 to >1010)		13	1.56 (0.67–3.61)		6	1.81 (0.47–7.04)
		89
T	0	54	.053	2	(Ref.)	< .001	11	(Ref.)	.001	3	(Ref.)
	1	29		4	4.65 (0.84–25.6)		16	4.66 (2.10–10.35)		8	6.88 (1.81–26.14)
N	0	83	.001	4	(Ref.)	< .001	24	(Ref.)	.002	9	(Ref.)
	1	5		2	9.86 (1.79–54.45)		3	6.74 (1.98–22.90)		2	8.03 (1.70–37.96)
Gleason score	0–7a	70	.004	2	(Ref.)	.004	17	(Ref.)	.003	5	(Ref.)
	>7a	19		4	8.02 (1.47–43.84)		10	2.96 (1.36–6.48)		6	5.09 (1.55–16.67)
Resection	R0	71	.007	3	(Ref.)	.001	18	(Ref.)	.015	7	(Ref.)
	R1	18		3	7.27 (1.36–38.78)		9	3.68 (1.64–8.26)		4	4.29 (1.21–15.23)
Fibronectin score	0	41	.031	3	(Ref.)	.086	11	(Ref.)	.004	4	(Ref.)
	1	36		0	-		13	1.98 (0.85–4.63)		4	2.48 (0.56–10.99)
	2	12		3	3390 (0 to >1010)		3	1.63 (0.49–5.47)		3	6.71 (1.72–26.08)
Fibronectin score	0 + 1	77	< .001	3	(Ref.)	.420	24	(Ref.)	.001	8	(Ref.)
	2	12		3	12.83 (2.46–66.92)		3	1.64 (0.49–5.49)		3	7.00 (1.77–27.64)

PSA indicates prostate-specific antigen; T, tumor size; N, nodal status; HR, hazard ratio; CI, confidence interval; Ref., reference. Significant P values are bolded.